About Microtubule-associated protein RP/EB family member 3
Microtubule-associated protein RP/EB family member 3 (MAPRE3) is a protein
from Homo sapiens identified by UniProt accession
Q9UPY8, 281 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Microtubule-associated protein RP/EB family member 3 |
|---|
| UniProt accession | Q9UPY8 |
|---|
| Gene | MAPRE3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 281 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (59)
Diseases linked to this target (Open Targets).
- cortical thickness · score 0.22
- neutrophil percentage of leukocytes · score 0.16
- brain measurement · score 0.16
- neuroimaging measurement · score 0.16
- cortical surface area measurement · score 0.14
- mathematical ability · score 0.11
- lymphocyte percentage of leukocytes · score 0.11
- urate measurement · score 0.10
- cognitive function measurement · score 0.10
- brain volume measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UPY8-F1 | alphafold | PREDICTED | 79.02 | — |
Amino-acid sequence (281 residues)
MAVNVYSTSV TSENLSRHDM LAWVNDSLHL NYTKIEQLCS GAAYCQFMDM LFPGCVHLRK VKFQAKLEHE YIHNFKVLQA AFKKMGVDKI IPVEKLVKGK FQDNFEFIQW FKKFFDANYD GKDYNPLLAR QGQDVAPPPN PGDQIFNKSK KLIGTAVPQR TSPTGPKNMQ TSGRLSNVAP PCILRKNPPS ARNGGHETDA QILELNQQLV DLKLTVDGLE KERDFYFSKL RDIELICQEH ESENSPVISG IIGILYATEE GFAPPEDDEI EEHQQEDQDE Y
Explore Microtubule-associated protein RP/EB family member 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets